Cirillo M
Institute of Internal Medicine and Metabolic Diseases, 2nd Medical School, University of Naples, Italy.
Am J Hypertens. 1990 Jul;3(7):570-2. doi: 10.1093/ajh/3.7.570.
Reduced calcium (Ca) binding capacity is a widespread and primary abnormality in SHR. It was reported that in red blood cell (RBC) membranes it is detectable only in membrane preparations containing sealed inside-out vesicles, the formation of which implies the partial removal of cytoskeletal proteins from the RBC membrane. The present study compares the Ca binding capacity of RBC membrane preparations with normal (+CS) and reduced (-CS) cytoskeleton content in SHR and normotensive WKY control rats. In addition to Ca binding capacity and protein content, the cholesterol content and the acetylcholinesterase (ACE) activity were measured as having a quantitative measure of integral membrane components in the different membrane preparations. In both strains the cholesterol/protein ratio, the ACE activity per mg of membrane protein, and the Ca binding capacity were all significantly higher in -CS compared to +CS membrane preparations (P less than .001). A statistically significant difference in Ca binding capacity between SHR and WKY was observed only using -CS membranes preparation. The results support the concept of a reduced membrane Ca binding capacity in rat genetic hypertension: this abnormality is detectable only in membrane preparations with reduced cytoskeletal content.
钙(Ca)结合能力降低是自发性高血压大鼠(SHR)中广泛存在的主要异常情况。据报道,在红细胞(RBC)膜中,只有在含有密封的内翻囊泡的膜制剂中才能检测到这种情况,而这种囊泡的形成意味着红细胞膜中的细胞骨架蛋白被部分去除。本研究比较了SHR和血压正常的WKY对照大鼠中具有正常(+CS)和降低(-CS)细胞骨架含量的红细胞膜制剂的钙结合能力。除了钙结合能力和蛋白质含量外,还测量了胆固醇含量和乙酰胆碱酯酶(ACE)活性,以定量测量不同膜制剂中整合膜成分的含量。在两个品系中,与+CS膜制剂相比,-CS膜制剂中的胆固醇/蛋白质比率、每毫克膜蛋白的ACE活性和钙结合能力均显著更高(P小于0.001)。仅使用-CS膜制剂时,观察到SHR和WKY之间的钙结合能力存在统计学显著差异。这些结果支持大鼠遗传性高血压中膜钙结合能力降低的概念:这种异常仅在细胞骨架含量降低的膜制剂中可检测到。